Past Issue

Volume 19, Supplement 1, Spring 2017 Pages: 113-117

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity


Pegah Larki, M.D., Ph.D., 1, Ehsan Gharib, Ph.D, 1, Mohammad Yaghoob Taleghani, M.Sc, 1, Fatemeh Khorshidi, M.Sc, 1, Ehsan Nazemalhosseini-Mojarad, Ph.D, 2, *, Hamid Asadzadeh Aghdaei, M.D., Ph.D, 1,
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Gastroenterology and Liver Disease Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding Address: P.O.Box 19857-17411 Gastroenterology and Liver Disease Research Center Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Yeman St Chamran Expressway Tehran Iran Email:Nazemalhosseini@sbmu.ac.ir

Abstract

The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic approach and predicting the epidermal growth factor receptor (EGFR)-targeted therapy resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur rarely in the colorectal cancers (CRCs) with the prevalence of less than 0.001% of the cases. In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested unless the patient is participating in a clinical trial enriching for the presence of KRAS or BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarcinoma of the colon showing the coexistence of KRAS and BRAF mutations and may have profound clinical implications for disease progression and therapeutic responses.